Retinal Diseases: Molecular Updates and Perspectives

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2178

Special Issue Editor

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China
Interests: angiogenesis; vascular biology; VEGFs, PDGFs; ocular neovascularization; vascular cell metabolism

Special Issue Information

Dear Colleagues,

Retinal diseases encompass a wide range of conditions that affect the retina, the light-sensitive tissue at the back of the eye. These diseases can lead to vision loss and significantly impact a person's quality of life. In recent years, advancements in molecular pathology, diagnostics, and treatments have revolutionized our understanding of retinal diseases.

This Special Issue aims to discuss and summarize insights into new molecular mechanisms and potential therapeutics for retinal diseases, such as age-related macular degeneration, diabetic retinopathy, inherited retinal diseases, glaucoma, myopia, and retinal vascular diseases.

We hope that the combination of original papers and focused reviews will provide a useful resource for advancements in the understanding of the molecular and cellular basis of retinal diseases, thus aiding researchers in the field and allowing others to take a step toward the discovery and intervention of vision-threatening diseases of the retina.

We look forward to your contributions.

Dr. Xuri Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 7474 KiB  
Article
HIF-1α Reduction by Lowering Intraocular Pressure Alleviated Retinal Neovascularization
by Ziqi Yang, Biyan Ni, Tian Zhou, Zijing Huang, Hong Zhou, Yang Zhou, Shiya Lin, Chang He and Xialin Liu
Biomolecules 2023, 13(10), 1532; https://doi.org/10.3390/biom13101532 - 17 Oct 2023
Cited by 1 | Viewed by 1716
Abstract
Hypoxia-induced retinal neovascularization is a leading cause of blindness worldwide. Oxygen-induced retinopathy (OIR) mouse, a well-established angiogenesis model, has been extensively used to evaluate the effect of anti-angiogenic agents through intravitreal injection. Here, we serendipitously found that the needles used for intravitreal injection [...] Read more.
Hypoxia-induced retinal neovascularization is a leading cause of blindness worldwide. Oxygen-induced retinopathy (OIR) mouse, a well-established angiogenesis model, has been extensively used to evaluate the effect of anti-angiogenic agents through intravitreal injection. Here, we serendipitously found that the needles used for intravitreal injection caused an unexpected “anti-angiogenic” effect in the OIR mice. To evaluate the effects of various intravitreal puncture sizes on retinal neovascularization and explore the potential underlying mechanism, intravitreal punctures using 0.5 mm (25 G), 0.3 mm (30 G), or 0.21 mm (33 G) needles were performed in OIR mice. Compared with 0.3 mm and 0.21 mm puncture, the 0.5 mm puncture remarkably suppressed the formation of pathological angiogenesis, inhibited vascular leakage, and remodeled the retinal vasculature. Mechanistically, the 0.5 mm puncture induced a substantial reduction in intraocular pressure (IOP), leading to an improvement in oxygen partial pressure (pO2) and significant reduction in Hif1a expression, resulting in resolution of angiogenic and inflammatory responses. Furthermore, IOP-lowering drugs, Travatan or Azarga, also promoted the alleviation of hypoxia and exhibited a potent anti-angiogenesis efficacy. Our study revealed an acute and significant reduction in IOP caused by a large puncture, which could remarkably suppress HIF-1α-mediated retinal neovascularization, indicating that lowering IOP may be a promising therapeutic avenue for treating retinal neovascular diseases. Full article
(This article belongs to the Special Issue Retinal Diseases: Molecular Updates and Perspectives)
Show Figures

Figure 1

Back to TopTop